Misplaced Pages

ABT-510

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Molecular therapeutic drug that was studied as a treatment for cancer
ABT-510
Names
IUPAC name (2S)-1-acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1Key: RIWLPSIAFBLILR-WVNGMBSFSA-N
SMILES
  • CCC(C(=O)N((C)CC)C(=O)N(CCCN=C(N)N)C(=O)N1CCC1C(=O)NCC)NC(=O)((C)O)NC(=O)((C)CC)NC(=O)(C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C
Properties
Chemical formula C46H83N13O11
Molar mass 994.250 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references
Chemical compound

ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."

Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.

References

  1. "2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)". J. Clin. Oncol. 22 (14S Suppl). July 15, 2004. 3080.
  2. NCI: ABT-510 Archived September 28, 2007, at the Wayback Machine
  3. Markovic SN, Suman VJ, Rao RA, et al. (June 2007). "A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma". Am. J. Clin. Oncol. 30 (3): 303–9. doi:10.1097/01.coc.0000256104.80089.35. PMID 17551310. S2CID 24673041.
Categories: